The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.

The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.

A method for preparing a probiotic preparation based on a W.sub.1/O/W.sub.2 double emulsion structure includes steps of: using a solution containing probiotics or a mixed solution of probiotics and a probiotic protective agent as an internal water phase W.sub.1; dissolving an emulsifier in a lipid phase O, and mixing the lipid phase O with the internal water phase W.sub.1; then preparing a primary emulsion W.sub.1/O by stirring and low-energy emulsification or high-energy emulsification; and using an emulsifier-contained solution as an external water phase W.sub.2, and adding the external water phase W.sub.2 to the primary emulsion W.sub.1/O; then preparing a W.sub.1/O/W.sub.2 double emulsion by stirring and the low-energy emulsification or the high-energy emulsification, thereby obtaining the probiotic preparation. The double emulsion system is used to embed the probiotics, which can keep the probiotics active during low-temperature storage and freezing and thawing.

A method for preparing a probiotic preparation based on a W.sub.1/O/W.sub.2 double emulsion structure includes steps of: using a solution containing probiotics or a mixed solution of probiotics and a probiotic protective agent as an internal water phase W.sub.1; dissolving an emulsifier in a lipid phase O, and mixing the lipid phase O with the internal water phase W.sub.1; then preparing a primary emulsion W.sub.1/O by stirring and low-energy emulsification or high-energy emulsification; and using an emulsifier-contained solution as an external water phase W.sub.2, and adding the external water phase W.sub.2 to the primary emulsion W.sub.1/O; then preparing a W.sub.1/O/W.sub.2 double emulsion by stirring and the low-energy emulsification or the high-energy emulsification, thereby obtaining the probiotic preparation. The double emulsion system is used to embed the probiotics, which can keep the probiotics active during low-temperature storage and freezing and thawing.

The invention described herein is related to the preparation and usage of nanoemulsions and nanoparticles which containing biological active ingredients including cosmetic, medical and pharmaceutical active ingredients to pass skin barriers and promote cell growth with evident clinical effects. Also, the present invention contains a cosmetic formulation that can be used for skin rejuvenation, wrinkle removal, scar treatment and wounds healing.

The invention described herein is related to the preparation and usage of nanoemulsions and nanoparticles which containing biological active ingredients including cosmetic, medical and pharmaceutical active ingredients to pass skin barriers and promote cell growth with evident clinical effects. Also, the present invention contains a cosmetic formulation that can be used for skin rejuvenation, wrinkle removal, scar treatment and wounds healing.